Results 1 to 10 of about 1,506 (149)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

Frontiers in Pediatrics, 2023
Selexipag, a selective prostacyclin receptor agonist, is approved for treating pulmonary arterial hypertension in WHO Group 1 adult patients. Compared to parenteral prostacyclin formulations, selexipag offers a significant improvement in patient’s and ...
Jenna M. Faircloth, Neelam D. Bhatt, Corey A. Chartan, Ryan D. Coleman, Natalie Villafranco, Fadel E. Ruiz, Raysa Morales-Demori, Elise Whalen, Erin Ely, Rozmeen Fombin, Nidhy P. Varghese   +10 more
exaly   +3 more sources

A selective agonist of the prostacyclin receptor alleviates microglial and astroglial neuroinflammatory responses through P38 and NLRP3 [PDF]

Frontiers in Immunology
IntroductionThe selective prostacyclin (IP) receptor agonist selexipag is FDA-approved for the treatment of pulmonary arterial hypertension. Selexipag also has anti-inflammatory effects in peripheral tissues, but the ability of selexipag to modulate ...
Hyun-ju Lee, Hyun-ju Lee, Sora Kang, Yoo Joo Jeong, Yoo Joo Jeong, Yoo Joo Jeong, Tae-Mi Jung, Jeong-Woo Hwang, Jeong-Woo Hwang, Ji-Yeong Jang, Ji-Yeong Jang, Ji-Yeong Jang, Chan-Hu Gu, Seokjun Oh, Jeong-Heon Song, Minho Moon, Hyang-Sook Hoe, Hyang-Sook Hoe, Hyang-Sook Hoe   +18 more
doaj   +2 more sources

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension

Pulmonary Circulation, 2020
Selexipag is an oral prostacyclin receptor agonist; it was recently approved for use in adults with pulmonary arterial hypertension. The safety and efficacy of selexipag has not yet been determined in the pediatric population.
Humberto Restrepo, Abraham Rothman
exaly   +2 more sources

Retrospective evaluation of Selexipag monotherapy on pulmonary hemodynamics in newly diagnosed, treatment-naïve patients with chronic thromboembolic pulmonary hypertension prior to balloon pulmonary angioplasty [PDF]

International Journal of Cardiology: Heart & Vasculature
Background: Selexipag has been approved for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in Japan since April 2021; however, its hemodynamic effects in treatment-naïve patients with inoperable CTEPH prior to balloon pulmonary ...
Naohiro Komura, Teruyasu Sugano, Toru Suzuki, Fumiaki Ono, Maria Abe, Uno Yamamoto, Keisuke Sekiya, Sho Kodama, Shintaro Minegishi, Shingo Kato, Kozo Okada, Junya Hosoda, Masaaki Konishi, Fumiyuki Otsuka, Noriaki Iwahashi, Tomoaki Ishigami, Daisuke Utsunomiya, Makoto Mo, Kiyoshi Hibi   +18 more
doaj   +2 more sources

Real-world Persistence on Selexipag for Pulmonary Arterial Hypertension in Canada [PDF]

CJC Open
Background: Safety and tolerability of selexipag in pulmonary arterial hypertension (PAH) was demonstrated in a phase 3 clinical trial. In this trial, up to 14% of patients receiving selexipag over a median period of 70 weeks prematurely discontinued ...
Jason Weatherald, MD, Steeve Provencher, MD, Jillian Murray, MPH, Matthew Badin, MBA, MSc, Shane Golden, MSc, Lisa Mielniczuk, MD, John Swiston, MD, Chang Zhang, PhD, Cindy Y.Y. Yip, PhD, Jean-Claude Mamputu, PhD, Brad Millson, MBS   +10 more
doaj   +2 more sources

Selexipag for the treatment of schistosomiasis-associated pulmonary arterial hypertension: the SELSCH study [PDF]

ERJ Open Research
Background Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is one of the most prevalent forms of PAH in Brazil. However, no prospective data are available for evaluating the efficacy of PAH drugs in the treatment of Sch-PAH.
Caio Julio Cesar dos Santos Fernandes, Susana Hoette, José Leônidas Alves-Jr, William Salibe-Filho, Carlos Vianna Poyares Jardim, Rogerio de Souza   +5 more
doaj   +2 more sources

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies) [PDF]

Drugs - Real World Outcomes
Background Treatment strategies for pulmonary arterial hypertension (PAH) depend on patients’ 1-year mortality risk; however, real-world practices and outcomes remain inadequately described.
Pilar Escribano Subias, Murali M. Chakinala, Kelly M. Chin, Eva-Maria Didden, Gurinderpal Doad, Harrison W. Farber, Sean Gaine, Anna R. Hemnes, Kristin B. Highland, Tobias J. Lange, Vallerie McLaughlin, Audrey Muller, Mohammad Rahman, Tatiana Remeňová, Stefan Söderberg, Apoorva Venkatesh, Nick H. Kim   +16 more
doaj   +2 more sources

Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

Pulmonary Circulation, 2018
We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH).
Georg Hansmann, Martin Koestenberger
exaly   +2 more sources

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study) [PDF]

Drugs - Real World Outcomes
Background In pulmonary arterial hypertension (PAH), comparative assessment of treatment effect on survival in randomized controlled settings of contemporary patients has not been feasible. Objective The aim of this study was to use EXPOSURE, the ongoing,
Stefan Söderberg, Pilar Escribano-Subias, Ciara Archey, Audrey Muller, Martina Fontana, Tobias J. Lange, Sean Gaine   +6 more
doaj   +2 more sources

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy

Drug Design, Development and Therapy, 2016
Elizabeth Ashley Hardin,1 Kelly M Chin2 1Department of Internal Medicine, Division of Cardiology, 2Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA ...
Kelly M Chin
exaly   +2 more sources